Tacrolimus Dose Optimization Strategy for Refractory Ulcerative Colitis Based on the Cytochrome P450 3A5 Polymorphism Prediction Using Trough Concentration after 24 Hours-Reference-Cited by-同舟云学术

Tacrolimus Dose Optimization Strategy for Refractory Ulcerative Colitis Based on the Cytochrome P450 3A5 Polymorphism Prediction Using Trough Concentration after 24 Hours

Published:2018 Issue:1 Volume:97 Page:90-96
ISSN:0012-2823
Container-title:Digestion
language:en
Short-container-title:Digestion

Author:

Onodera Motoyuki,Endo Katsuya,Naito Takeo,Moroi Rintaro,Kuroha Masatake,Kanazawa Yoshitake,Kimura Tomoya,Shiga Hisashi,Kakuta Yoichi,Negoro Kenichi,Kinouchi Yoshitaka,Shimosegawa Tooru

Publisher

S. Karger AG

Subject

Gastroenterology

Reference24 articles.

1. Saito E, Nagahori M, Fujii T, et al: Efficacy of salvage therapy and its effect on operative outcomes in patients with ulcerative colitis. Digestion 2014; 89: 55–60.

2. Hirai F, Takatsu N, Yano Y, et al: Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus. J Gastroenterol Hepatol 2014; 29: 60–66.

3. Endo K, Onodera M, Shiga H, et al: A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. Gastroenterol Res Pract 2016; 2016: 3162595.

4. Yamamoto T, Shimoyama T, Umegae S, et al: Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study. Aliment Pharmacol Ther 2016; 43: 705–716.

5. Onodera M, Endo K, Kakuta Y, et al: ATP-binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis. J Gastroenterol Hepatol 2017; 32: 1562–1569.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug–drug interaction between tacrolimus and caspofungin in Chinese kidney transplant patients with different CYP3A5 genotypes;Therapeutic Advances in Drug Safety;2024-01

2. CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients;Annals of Pharmacotherapy;2023-09-13

3. Efficacy of Tacrolimus in Uveitis, and the Usefulness of Serum Tacrolimus Levels in Predicting Disease Control. Results from a Single Large Center;Ocular Immunology and Inflammation;2021-06-14

4. Optimization of Administrative Efficiency and Educational Methods Based on Information Technology;2021 2nd International Conference on Computers, Information Processing and Advanced Education;2021-05-25

5. Advances in research of tacrolimus for treatment of inflammatory bowel disease;World Chinese Journal of Digestology;2019-07-08